Affimed N.V. (AFMD), a clinical stage biopharmaceutical company that focuses on oncology drugs, Wednesday reported net losses that narrowed in 2018, helped by higher revenues. Net loss fell to €0.32 per share from €0.69 per share a year ago.
The bottom line was partially offset by a 64% hike in research and development expenses during this period, which was due to higher expenses for AFM13 and AFM11 clinical development activities, as well as early-stage development and discovery activities.
Revenues for the year rose to €23.7 million from €2 million in 2017.
CEO Dr. Adi Hoess said, “With our current financial resources, we believe we are well-positioned to achieve additional milestones in 2019 and beyond, including advancing our lead development candidate, AFM13, into a market registration-directed study and entering the clinic with AFM24, our second innate cell engager and a potential treatment for multiple solid tumor malignancies.”
Cash, cash equivalents and current financial assets jumped to €108.8 million as of December 31, 2018,
from €39.8 million during the same period last year.
AFMD shares ended its last trading session 1.75% in green on Tuesday.
READ: ONCONOVA THERAPEUTICS NARROWS LOSSES IN 2018
The stock got a major fillip when it announced in August last year a strategic deal with Genentech to develop and commercialize NK cell engager-based immunotherapeutics to treat multiple cancers. Genentech a member of Swiss multinational healthcare company Roche Group.
Buoyed by this news, the stock has more-than-doubled over the trailing 52 weeks. In the year-to-date period, Affimed shares have increased 25%, primarily helped by a 9% rally earlier this month when the German company said it would receive an undisclosed amount triggered by the achievement of a preclinical milestone under its ongoing strategic collaboration with Genentech.
Browse through our earnings calendar and get all scheduled earnings announcements, analyst/investor conference and much more!
Most Popular
Johnson & Johnson to report Q2 earnings on July 16. Here’s what to expect
Johnson & Johnson's (NYSE: JNJ) business strategy for fiscal 2025 is focused on reducing the impact of patent expirations on its revenue. Anticipating sales to benefit from growth initiatives, including
What to expect when United Airlines (UAL) reports its Q2 2025 earnings results
Shares of United Airlines Holdings, Inc. (NASDAQ: UAL) stayed green on Tuesday. The stock has gained 44% over the past three months. The airline company is scheduled to report its
Earnings Preview: Fastenal Company likely to report higher Q2 sales and profit
Fastenal Company (NASDAQ: FAST), a leading provider of industrial and construction supplies, is set to publish its second-quarter results next week. The company is among the hardest hit by the
